The research team set out to answer a deceptively simple question: at a major United States academic medical center, what proportion of patients with metastatic EGFR-mutated non-small-cell lung cancer actually receive second-line therapy after discontinuing first-line osimertinib? Prior real-world studies had painted a grim picture. An Italian cohort found that only 56 percent of patients who progressed on first-line osimertinib received further treatment. A European retrospective analysis reported that just 42 percent of 500 patients who started the drug went on to a second line, with 292 dying before any further therapy. A large United States community-based study found a second-line rate of 56 percent. Whether elite academic centers, with their multidisciplinary tumor boards, clinical trial portfolios, and abundant resources, might do better remained an open question, and one with real implications for how the FLAURA2 results should be interpreted.

To investigate, the researchers combed through medical records of patients treated at their institution between February 2018 and July 2024, ultimately identifying 115 evaluable patients with metastatic disease harboring a classical EGFR mutation, either an exon 19 deletion or the L858R substitution, who had been treated with first-line osimertinib monotherapy. The cohort was notably diverse: half the patients were Asian, 74 percent were women, 69 percent had never smoked, and 93 percent had adenocarcinoma histology. The median age at diagnosis was 69 years, eight years older than the median in FLAURA2. Thirty-seven percent had central nervous system involvement at diagnosis, a detail that matters because osimertinib’s ability to penetrate the blood-brain barrier is one of its clinical strengths. All patients underwent next-generation sequencing-based molecular profiling at diagnosis, with the single exception of six patients whose limited tissue samples permitted only rapid targeted PCR testing for EGFR.

The headline finding was sobering. Of the 115 patients, 57.4 percent, or 66 individuals, discontinued first-line osimertinib during the observation window. Among those 66 patients, 39.4 percent died or entered hospice without receiving further anticancer treatment, while 60.6 percent, or 40 patients, experienced disease progression and went on to second-line therapy. In other words, even at a well-resourced academic center in one of the world’s most medically dense cities, only about six in ten patients who stopped osimertinib lived long enough and remained well enough to receive another treatment. When the researchers ran a conservative sensitivity analysis assuming that ten patients lost to follow-up had also discontinued therapy without receiving a second line, the second-line rate fell to 52.6 percent. The conclusion was hard to escape: the FLAURA2 control arm, far from being an outlier, mirrored real-world academic practice with uncomfortable fidelity.

Beyond the second-line question, the study yielded rich survival data. Median time to treatment failure on first-line osimertinib was 25.3 months, consistent with prior reports of osimertinib’s effectiveness. For the 40 patients who reached second-line therapy, median time to treatment failure dropped sharply to 4.7 months, and for the 22 who reached third-line therapy it was 4.8 months, underscoring how quickly options narrow after the first targeted agent fails. Median overall survival for the entire cohort was 42.4 months. Roughly half of the patients still on first-line osimertinib at the data cutoff had been on treatment for at least 24 months, while the other half had been on it for less time, a reminder that a substantial fraction of patients derive durable benefit from the drug even as others slip away.

One of the study’s most striking findings concerned the tumor suppressor gene TP53. Nearly half of the patients, 48 percent, carried a concurrent TP53 mutation in their tumors, and the vast majority of these were classified as likely oncogenic in the OncoKB knowledgebase. Patients with TP53-mutated tumors fared dramatically worse: their median time to treatment failure was 15.7 months compared with 42.2 months for those with TP53 wild-type tumors, and their median overall survival was 29.6 months compared with a figure that had not yet been reached for the wild-type group at a lower bound of 63.5 months. In multivariate Cox regression controlling for age, race, central nervous system disease, smoking status, and EGFR mutation type, TP53 status remained independently significant, with adjusted hazard ratios of 4.69 for treatment failure and 4.25 for death. Age was the only other covariate that retained significance.

Who, then, was falling through the cracks? The data pointed squarely at age and frailty. Patients who did not receive second-line therapy had a median age of 77.7 years, more than a decade older than the median of 64.9 years among those who did, a difference that was highly statistically significant. Performance status told a related story: among patients with good performance status at diagnosis, 62.2 percent of those who discontinued osimertinib went on to second-line treatment, compared with 47.4 percent of those with poor performance status, though this difference did not reach statistical significance. Notably, most patients who entered hospice after progression had poor performance status at hospice initiation, and nearly half had declined from good to poor status between diagnosis and hospice. Interestingly, central nervous system disease at diagnosis made no difference in second-line rates, perhaps reflecting osimertinib’s efficacy against brain metastases, and TP53 mutation status also did not significantly alter the likelihood of receiving further treatment.

The regimens patients actually received after osimertinib reflected contemporary National Comprehensive Cancer Network recommendations. Chemotherapy dominated the second-line landscape at 72.5 percent of patients, followed by continuation of osimertinib alongside another agent at 22.5 percent, immune checkpoint inhibitors at 17.5 percent, and vascular endothelial growth factor inhibitors and amivantamab at 7.5 percent each. Third-line patterns were similar, with chemotherapy again most common at 50 percent. Attrition continued relentlessly down the line: of 40 patients on second-line therapy, 33 discontinued it, and 22 of those proceeded to a third line. The funnel narrows at every step, and each narrowing represents patients who died, entered hospice, or were too ill to continue.

The findings carry weighty implications for treatment strategy. Because so many patients never reach a second line, the authors argue that patients who are willing and eligible at diagnosis should consider receiving chemotherapy together with osimertinib upfront, regardless of TP53 status, rather than saving chemotherapy for later. Emerging evidence strengthens this logic: a post hoc analysis of the MARIPOSA trial showed that the combination of amivantamab and lazertinib improved overall survival specifically in patients with TP53 mutations, and the recently reported TOP trial found that adding chemotherapy to osimertinib extended progression-free survival from 15.6 to 34.0 months in patients with EGFR mutations and TP53 co-mutations, though overall survival data remain immature. The counterweight is toxicity, since both FLAURA2 and MARIPOSA showed that combination regimens roughly doubled the rate of grade 3 adverse events, and identifying which patients can safely avoid intensification, possibly through circulating tumor DNA monitoring, remains a crucial unanswered question.

Ultimately, the study’s most viral-worthy message may be its most uncomfortable one: the attrition between first-line and second-line treatment in metastatic EGFR-mutated lung cancer is not a trial artifact, a community-practice problem, or a resource issue that better institutions can simply fix. Roughly half of patients with metastatic disease, across driver mutations and treatment regimens, never receive a second line of therapy, and this single-institution academic cohort proved no exception. The gap between the promise of precision oncology and its delivery at the bedside persists even where the tools are most available, and closing it will require confronting the realities of age, declining performance status, and the biology of aggressive disease rather than assuming that excellence in one line of treatment guarantees a chance at the next.

Subject of Research: Second-line treatment patterns and outcomes after first-line osimertinib in metastatic EGFR-mutated non-small-cell lung cancer

Article Title: Second‐Line Therapy Following Osimertinib in Metastatic EGFR‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center

Article References: Rafizadeh, M., Bogdan, S., Lee, J., Garcia, C., Saxena, A., Zhou, K., & Parang, B. (2026). Second‐Line Therapy Following Osimertinib in Metastatic EGFR ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center. Cancer Reports, 9(9), Article e70693. https://doi.org/10.1002/cnr2.70693

Image Credits: AI Generated

DOI: 10.1002/cnr2.70693

Keywords: osimertinib, EGFR-mutated NSCLC, second-line therapy, FLAURA2, TP53 mutation, lung cancer, real-world evidence, chemotherapy combination, time to treatment failure, overall survival, academic medical center, precision oncology